Pathology: mHNSCC - L2 - all population; mHNSCC - L2 - PDL1 positive;
| mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 positive | ||||
| EAGLE (D vs ICC), 2019 | CheckMate 141, 2016 | KEYNOTE-040 (all population), 2018 | KEYNOTE-040 (CPS >1), 2018 | ||
| pembrolizumab alone | 2 | T1 | T1 | ||
| durvalumab alone | 1 | T1 | |||
| nivolumab alone | 1 | T1 | |||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 |